Artiva Biotherapeutics appoints Dr. Dan Baker to its Board, enhancing expertise in drug development for autoimmune diseases and cancers.
Quiver AI Summary
Artiva Biotherapeutics, Inc. has announced the appointment of Dr. Dan Baker as an independent member of its Board of Directors. Dr. Baker, who has over 20 years of experience in drug development, brings significant expertise in immunology and clinical strategy, having previously worked at Johnson & Johnson and led the development of major immunology drugs. Artiva, a clinical-stage biotechnology company focused on creating safe and effective cell therapies for autoimmune diseases and cancers, aims to leverage Dr. Baker's insights as it advances its AlloNK® program, an innovative NK cell therapy currently in clinical trials for systemic lupus erythematosus and other autoimmune conditions. Dr. Baker expressed enthusiasm for collaborating with Artiva to support its mission in developing NK cell-based therapies.
Potential Positives
- Appointment of Dr. Dan Baker to the Board of Directors enhances Artiva’s leadership with significant industry experience in drug development and immunology.
- Dr. Baker's background includes key roles in the development of major immunology therapies that have achieved over $20 billion in peak sales, indicating strong potential for strategic guidance.
- Artiva’s AlloNK® program, which Dr. Baker will support, represents an innovative approach to treating autoimmune diseases, aligning with the company's mission to advance accessible therapies.
- The press release highlights Artiva's clinical trial involvement for AlloNK®, showcasing their commitment to advancing cutting-edge treatments in the biotechnology sector.
Potential Negatives
- The press release contains a significant reliance on forward-looking statements, which may create skepticism among investors regarding the company’s actual capabilities and future performance.
- There is an implication of potential risk factors associated with the company’s clinical programs that could hinder progress, as highlighted in the mention of the “Risk Factors” in the SEC filings.
- The reliance on Dr. Baker's previous experience suggests a need for external expertise, which may indicate a lack of sufficient internal capability or resources to navigate their complex clinical development processes independently.
FAQ
What recent appointment was announced by Artiva Biotherapeutics?
Artiva Biotherapeutics announced the appointment of Dan Baker, M.D., to its Board of Directors.
How does Dr. Baker's experience benefit Artiva Biotherapeutics?
Dr. Baker brings over two decades of drug development expertise, particularly in autoimmune disease treatments.
What is the AlloNK® program at Artiva Biotherapeutics?
AlloNK® is an allogeneic NK cell therapy candidate aimed at enhancing B-cell depletion in autoimmune diseases.
What are Artiva's main areas of focus?
Artiva focuses on developing cell therapies for autoimmune diseases and cancers through innovative NK cell technology.
Where is Artiva Biotherapeutics headquartered?
Artiva Biotherapeutics is headquartered in San Diego, California.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker brings over two decades of drug development experience in the pharmaceutical industry. He is currently the interim Chief Development Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at Johnson & Johnson (Janssen/Centocor) (J & J) most recently as the Vice President of Immunology R&D.
“Dan is a pharmaceutical industry veteran who brings decades of leadership experience in clinical and regulatory strategy to our Board of Directors. Importantly, he has invaluable experience in the clinical development of treatments for autoimmune disease, including key standards of care therapies such as Remicade, Simponi and Stelara,” said Fred Aslan, M.D., Chief Executive Officer (CEO) of Artiva. “We are delighted to welcome Dan to our Board and leverage his unique insights and experience as we advance and expand the development of our AlloNK
®
program.”
Dr. Baker added, “Artiva is pioneering novel NK cell therapies with unmatched versatility and broad expansion potential across autoimmune diseases. I look forward to partnering with the management team and the board to support them in their mission to deliver safe and effective NK cell-based therapies that can be used in a community setting.”
Prior to Cue Biopharma, Inc., Dr. Baker served as CEO and Founder of Kira Biotech Pty Ltd, a biotechnology company advancing novel drugs targeting immune system disorders. During his tenure at J & J, he led the clinical development of major immunology and inflammatory drugs including Remicade, Simponi and Stelara, which achieved over $20 billion in peak sales as well as other major clinical drug programs. Dr. Baker also previously served as Executive Director on the board of directors of Galapagos Therapeutics. He holds a B.A. in Biology from Gettysburg College and an M.D. from the University of Pennsylvania. Dr. Baker completed his medical residency at Hershey Medical Center and fellowship in Rheumatology at the University of Pennsylvania, followed by a research fellowship in Rheumatology at Mass General Hospital. He continued on as part of the faculty of the University of Pennsylvania for 18 years before taking on industry roles.
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK
®
, is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK
®
is currently in clinical trials for treatment of systemic lupus erythematosus, for patients with or without lupus nephritis, and in an investigator-initiated basket trial in multiple autoimmune indications. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.
Artiva is headquartered in San Diego, California. For more information, please visit https://www.artivabio.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Artiva Biotherapeutics, Inc. (the “Company”) regarding the potential benefits, accessibility, effectiveness and safety of AlloNK
®
. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investors: Neha Krishnamohan,
Artiva Biotherapeutics
,
ir@artivabio.com
Media: Jessica Yingling, Ph.D.,
Little Dog Communications Inc.
,
jessica@litldog.com
, +1.858.344.8091
Source: Artiva Biotherapeutics, Inc.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
